Industry Attorneys Criticize FDA’s Emerging Signals Draft Guidance
This article was originally published in The Gray Sheet
Executive Summary
A recent draft guidance from FDA establishing a process for issuing early public warnings of possible safety risks linked to devices is raising the hackles of industry attorneys and advocates who say the warnings could confuse patients, lead them to avoid appropriate use of devices and increase the likelihood of frivolous lawsuits.
You may also be interested in...
FDA Drafts Plan To Publicize 'Emerging Signals' Of Device Risks
In a draft guidance, FDA explains how it plans to communicate signs of postmarket device risks before it has performed a full analysis or developed specific recommendations. Public health advocates say it is a positive move to get ahead of potential safety problems early. The agency is seeking comment from companies on whether it needs to consult with firms prior to releasing information on emerging signals about their devices.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.